Upgrade to SI Premium - Free Trial

DMRA (DMRA)

21.49 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/2/26)

Latest Headlines

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 2, 2026 7:59 AM - StreetInsider Form 4 Damora Therapeutics, For: Sep 25 Filed by: Jarrett Jennifer September 28, 2026 7:00 AM - SEC Filing Damora Therapeutics (DMRA) PT Raised to $60 at Guggenheim September 25, 2026 6:26 AM - StreetInsider Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 3, 2026 8:00 AM - StreetInsider TD Cowen Assumes Damora Therapeutics (DMRA) at Buy August 22, 2026 7:54 AM - StreetInsider Form 4 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew August 13, 2026 5:00 PM - SEC Filing Form 3 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew August 13, 2026 4:55 PM - SEC Filing Form EFFECT Damora Therapeutics, August 13, 2026 6:06 AM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:28 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:27 PM - SEC Filing Form POSASR Damora Therapeutics, August 10, 2026 5:25 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:23 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:20 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:19 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:16 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:15 PM - SEC Filing Form S-8 POS Damora Therapeutics, August 10, 2026 5:13 PM - SEC Filing Form POS AM Damora Therapeutics, August 10, 2026 4:45 PM - SEC Filing Form 8-A12B/A Damora Therapeutics, August 10, 2026 4:15 PM - SEC Filing Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights August 10, 2026 4:05 PM - Globe NewsWire Form 10-Q Damora Therapeutics, For: Jun 30 August 10, 2026 4:01 PM - SEC Filing Form 144 Damora Therapeutics, Filed by: Firmani Lori August 6, 2026 11:35 AM - SEC Filing Damora starts Phase 1/1b trial of DMR-001 for blood disorders August 5, 2026 8:01 AM - StreetInsider Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis August 5, 2026 8:00 AM - Globe NewsWire Full Article List